Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1830458 | 0.90 | TSHR (0.57) | TSHRLMNAHPGDSMN1; SMN2GAA | |
| SCHEMBL1671124 | 0.88 | TSHR (0.55) | TSHRLMNAHPGDSMN1; SMN2GAA | |
| SCHEMBL1205921 | 0.88 | TSHR (0.47) | TSHRLMNAHPGDGAAATR | |
| SCHEMBL30965061 | 0.86 | TSHR (0.46) | TSHRLMNAHPGDSMN1; SMN2GAA | |
| SCHEMBL7930745 | 0.86 | TSHR (0.46) | TSHRLMNAHPGDSMN1; SMN2GAA | |
| SCHEMBL27434364 | 0.84 | L3MBTL1 (0.44) | TSHRLMNAHPGDGAAATR | |
| SCHEMBL134817 | 0.84 | ALDH1A1 (0.61) | TSHRLMNAHPGDGAAATR | |
| SCHEMBL6629351 | 0.84 | ROCK2 (0.46) | TSHRGAAATRL3MBTL1NAMPT | |
| SCHEMBL9932144 | 0.84 | PTGES (0.57) | TSHRLMNAHPGDSMN1; SMN2CYP4F2 | |
| SCHEMBL5129905 | 0.83 | GAA (0.50) | TSHRLMNAHPGDSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006257-B2 | Bicyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006257-B2 | Bicyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006257-B2 | Bicyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| WO-2014167444-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-10-16 | — | — | WO | disclosed |
| US-20130210844-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130210844-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130210844-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2013118071-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013072825-A1 | PHTALAZINONE DERIVATIVES AS MPEGS -1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013072825-A1 | PHTALAZINONE DERIVATIVES AS MPEGS -1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210844-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | TSHR 3909/4885LMNA 3409/4885HPGD 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.